A five-protein prognostic signature with GBP2 functioning in immune cell infiltration of clear cell renal cell carcinoma
暂无分享,去创建一个
Qing-Yu He | C. Zhang | Kun Meng | Yun-Long Pan | Dan Liu | Lili Hu | Yu-ying Li
[1] Xiaogang Wang,et al. GBP2 as a potential prognostic predictor with immune-related characteristics in glioma , 2022, Frontiers in Genetics.
[2] Xiaogang Wang,et al. GBP2 facilitates the progression of glioma via regulation of KIF22/EGFR signaling , 2022, Cell death discovery.
[3] Hongyan Guo,et al. Multi-omics approaches for biomarker discovery in early ovarian cancer diagnosis , 2022, EBioMedicine.
[4] Jing Liu,et al. Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target , 2022, Journal for ImmunoTherapy of Cancer.
[5] Xiaoying Hu,et al. The JAK/STAT signaling pathway: from bench to clinic , 2021, Signal Transduction and Targeted Therapy.
[6] Ryan C. Kalb,et al. The Large GTPase, GBP-2, Regulates Rho Family GTPases to Inhibit Migration and Invadosome Formation in Breast Cancer Cells , 2021, Cancers.
[7] Z. Shao,et al. Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response , 2021, Journal of Hematology & Oncology.
[8] P. He,et al. GBP2 as a potential prognostic biomarker in pancreatic adenocarcinoma , 2021, PeerJ.
[9] C. Leslie,et al. Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy. , 2021, Cancer cell.
[10] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[11] Q. Lan,et al. GBP5 drives malignancy of glioblastoma via the Src/ERK1/2/MMP3 pathway , 2021, Cell Death & Disease.
[12] B. Győrffy,et al. Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis , 2021, Computational and structural biotechnology journal.
[13] Q. Lan,et al. GBP2 enhances glioblastoma invasion through Stat3/fibronectin pathway , 2020, Oncogene.
[14] J. O’Shea,et al. SnapShot: Jak-STAT Signaling II , 2020, Cell.
[15] B. Dai,et al. Identification and validation of dichotomous immune subtypes based on intratumoral immune cells infiltration in clear cell renal cell carcinoma patients , 2020, Journal for ImmunoTherapy of Cancer.
[16] Bin Hu,et al. Guanylate‐binding protein‐2 inhibits colorectal cancer cell growth and increases the sensitivity to paclitaxel of paclitaxel‐resistant colorectal cancer cells by interfering Wnt signaling , 2020, Journal of cellular biochemistry.
[17] C. Barbas,et al. Mass spectrometry based proteomics and metabolomics in personalized oncology. , 2020, Biochimica et biophysica acta. Molecular basis of disease.
[18] M. Rugge,et al. PD‐L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus , 2019, Cancer medicine.
[19] K. Tretina,et al. Interferon-induced guanylate-binding proteins: Guardians of host defense in health and disease , 2019, The Journal of experimental medicine.
[20] R. Shamir,et al. Multi-omic and multi-view clustering algorithms: review and cancer benchmark , 2018, bioRxiv.
[21] P. Golstein,et al. An early history of T cell-mediated cytotoxicity , 2018, Nature Reviews Immunology.
[22] C. Hutter,et al. The Cancer Genome Atlas: Creating Lasting Value beyond Its Data , 2018, Cell.
[23] J. Foekens,et al. T lymphocytes facilitate brain metastasis of breast cancer by inducing Guanylate-Binding Protein 1 expression , 2018, Acta Neuropathologica.
[24] M. M. Dias,et al. Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer , 2017, BMC Cancer.
[25] Juan Zhang,et al. Guanylate-binding protein 2 regulates Drp1-mediated mitochondrial fission to suppress breast cancer cell invasion , 2017, Cell Death and Disease.
[26] Yuka Kanno,et al. Mechanisms and consequences of Jak–STAT signaling in the immune system , 2017, Nature Immunology.
[27] Ting Wu,et al. Tumor microenvironment and therapeutic response. , 2017, Cancer letters.
[28] Brendan MacLean,et al. CPTAC Assay Portal: a repository of targeted proteomic assays , 2014, Nature Methods.
[29] L. Chin,et al. Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma , 2011, The Journal of experimental medicine.
[30] Gary D. Bader,et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function , 2010, Nucleic Acids Res..
[31] M. Mann,et al. Universal sample preparation method for proteome analysis , 2009, Nature Methods.
[32] S. Horvath,et al. WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.
[33] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.